Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Exclusive Enteral Nutrition Mediates Beneficial Gut Microbiome Enrichment in Acute Severe Colitis.

Bajaj A. et al, (2024), Inflamm Bowel Dis, 30, 641 - 650

Study protocol for a Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent-shunt in Acute Variceal Bleeding (REACT-AVB trial).

Tripathi D. et al, (2024), BMJ Open Gastroenterol, 11

Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial.

Jairath V. et al, (2024), BMJ Open Gastroenterol, 11

Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.

Lindsay JO. et al, (2024), Lancet Gastroenterol Hepatol

Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials.

Pai RK. et al, (2024), Expert Rev Gastroenterol Hepatol, 18, 73 - 87

Letter: 'No first among equals'.

Arora U. et al, (2023), Aliment Pharmacol Ther

Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards.

Uhlig HH. et al, (2023), Nat Rev Gastroenterol Hepatol

Inflammation across tissues: can shared cell biology help design smarter trials?

Hosack T. et al, (2023), Nat Rev Rheumatol, 19, 666 - 674

The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis.

Travis S. et al, (2023), Inflamm Bowel Dis

Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions.

Dubinsky M. et al, (2023), Am J Gastroenterol

JAK inhibitor, a new player for treatment-refractory microscopic colitis.

Druez A. et al, (2023), Intest Res, 21, 411 - 412

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.

Barnes E. et al, (2023), Nat Med, 29, 1760 - 1774

Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.

Wong S-Y. et al, (2023), Inflamm Bowel Dis

Development of the Escalation of Therapy or Intervention (ETI) calculator for patients with ulcerative colitis using ePROMS.

Matini L. et al, (2023), J Crohns Colitis

Genome-Wide Methylation Profiling in 229 Patients With Crohn's Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn's Disease (TOPPIC).

Ventham NT. et al, (2023), Cellular and molecular gastroenterology and hepatology, 16, 431 - 450

Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions.

Ahmad HA. et al, (2023), Intest Res

The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease.

Horrigan JM. et al, (2023), Crohns Colitis 360, 5

Vedolizumab for the Treatment of Chronic Pouchitis.

Travis S. et al, (2023), N Engl J Med, 388, 1191 - 1200

APOLLO Has Landed: PROMS and Histology in UC.

Bryant RV. and Travis SPL., (2023), J Crohns Colitis

Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials.

Ahmad HA. et al, (2023), J Crohns Colitis

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?